| Effects of bisphosphonates on lipid metabolism. | |
| | |
MedLine Citation:
|
PMID: 18404138 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVES: Bisphosphonates are widely used for the treatment of metabolic bone disorders and their effects on lipid metabolism have also been investigated. Some studies reported that bisphosphonates have beneficial effects on serum cholesterol levels. In this study we aimed to assess the effects of bisphosphonates on lipid levels in hyperlipidemic patients who received bisphosphonates because of osteoporosis. METHODS: 49 female patients (age: 54.2+/-7.2 years) with diagnosis of osteoporosis and hyperlipidemia were enrolled. Patients received alendronate 10 mg/day and they were followed up for 6 months. Pretreatment total cholesterol, triglyceride, HDL-cholesterol, LDL-cholesterol, apolipoprotein A1 and apolipoprotein B levels were measured and compared with post-treatment levels. RESULTS: Pretreatment and post-treatment levels of total cholesterol were 255.2+/-34.3; 233.02+/-37.0 mg/dL, triglyceride levels were 153.0+/-57.3; 129.1+/-54.4 mg/dL, and LDL levels were 170.7+/-30.5; 160.0+/-34.2 mg/dL, respectively. Reductions in total cholesterol, triglyceride and LDL-cholesterol levels were statistically significant; whereas differences in HDL-cholesterol, apolipoprotein-A1 and apolipoprotein-B levels were not significant. CONCLUSIONS: Data from our study suggest that alendronate therapy may have beneficial effects on lipid metabolism. Thus, when hyperlipidemia is detected in patients receiving bisphosphonates, it is considered reasonable to follow the patient for a while before initiating antihyperlipidemic agent to prevent unnecessary use of drugs. |
| | |
Authors:
|
Engin Guney; Gurcan Kisakol; A Gokhan Ozgen; Candeger Yilmaz; Taylan Kabalak |
Related Documents
:
|
8130968 - Plasma lipid, lipoprotein and apolipoprotein profiles in nigerian university athletes a... 10888968 - Do triglycerides provide meaningful information about heart disease risk? 20526038 - Serum total and non-high-density lipoprotein cholesterol and the risk prediction of car... 18433708 - Adolescent cholesterol metabolism predicts coronary risk factors at middle age: the car... 9181258 - Delayed increase in blood pressure induced by spontaneously hypertensive rat plasma aft... 8130968 - Plasma lipid, lipoprotein and apolipoprotein profiles in nigerian university athletes a... |
Publication Detail:
|
Type: Clinical Trial; Journal Article |
Journal Detail:
|
Title: Neuro endocrinology letters Volume: 29 ISSN: 0172-780X ISO Abbreviation: Neuro Endocrinol. Lett. Publication Date: 2008 Apr |
Date Detail:
|
Created Date: 2008-04-29 Completed Date: 2008-06-25 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 8008373 Medline TA: Neuro Endocrinol Lett Country: Sweden |
Other Details:
|
Languages: eng Pagination: 252-5 Citation Subset: IM |
Affiliation:
|
Department of Endocrinology, Medical Faculty of Adnan Menderes University, Aydin, Turkey. enginguney@hotmail.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Alendronate
/
pharmacology,
therapeutic use Bone Density Conservation Agents / pharmacology, therapeutic use Diphosphonates / pharmacology*, therapeutic use Female Humans Lipid Metabolism / drug effects* Lipids / blood Middle Aged Osteoporosis, Postmenopausal / blood, drug therapy |
| Chemical | |
Reg. No./Substance:
|
0/Bone Density Conservation Agents; 0/Diphosphonates; 0/Lipids; 66376-36-1/Alendronate |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Laparoscopic management of ectopic pregnancy.
Next Document: Effects of acute L-carnitine intake on metabolic and blood lactate levels of elite badminton players...